Market Place
Sourcing Support
Arcellx iMMagine-1 Study Data for Relapsed/Refractory Myeloma
08 Dec 2024 //
BUSINESSWIRE
Arcellx Provides Q3 2024 Financial Results & Business Highlights
07 Nov 2024 //
BUSINESSWIRE
Arcellx to Present Data for Ph 1 Study in Multiple Myeloma at ASH
05 Nov 2024 //
BUSINESSWIRE
Arcellx Provides Second Quarter 2024 Financial Results and Business Updates
08 Aug 2024 //
BUSINESSWIRE
Kite & Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma
11 May 2024 //
PHARMABIZ
Arcellx Provides First Quarter 2024 Financial Results
09 May 2024 //
BUSINESSWIRE
Kite, Arcellx Advances In Anti-Cel Multiple Myeloma Program
09 May 2024 //
BUSINESSWIRE
Arcellx & Kite Continue Momentum with Advances in Multiple Myeloma Program
09 May 2024 //
BUSINESSWIRE
Arcellx to Participate in Two Upcoming Investor Conferences
07 May 2024 //
BUSINESSWIRE
Arcellx to Participate at 23rd Needham Healthcare Conference
04 Apr 2024 //
PRESS RELEASE
Arcellx to Participate at the H.C. 2nd Annual Cell Therapy Virtual Conference
20 Mar 2024 //
BUSINESSWIRE
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results
28 Feb 2024 //
PR NEWSWIRE
Arcellx, Kite aim to keep chipping away at Carvykti advantage
09 Dec 2023 //
ENDPTS
Arcellx Announces Continued Responses from Its CART-ddBCMA Phase 1 Trial
08 Dec 2023 //
PR NEWSWIRE
Gilead deepens Arcellx pact to include lymphomas
16 Nov 2023 //
PR NEWSWIRE
Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights
13 Nov 2023 //
PR NEWSWIRE
Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial
02 Nov 2023 //
PR NEWSWIRE
Arcellx to Participate in Two Upcoming Investor Conferences
26 Oct 2023 //
PRESS RELEASE
FDA Lifts Partial Hold on Arcellx’s Multiple Myeloma Trial After Patient Death
16 Aug 2023 //
BIOSPACE
FDA Hold on Arcellx’s Multiple Myeloma Cell Therapy Trial After Patient Death
21 Jun 2023 //
BIOSPACE
Arcellx Provides First Quarter Financial Results
08 May 2023 //
PRESS RELEASE
Canaccord Genuity Maintains Arcellx (ACLX) Buy Recommendation
20 Apr 2023 //
NASDAQ
Kite And Arcellx Close Agreement To Co-Develop CART-DdBCMA In Multiple Myeloma
30 Jan 2023 //
PRESS RELEASE
Kite and Arcellx partner to advance blood cancer cell therapy
03 Jan 2023 //
BIOPROCESSINTL
Gilead buys into multiple myeloma cell therapy with Arcellx deal
10 Dec 2022 //
BIOPHARMADIVE
Kite and Arcellx Announce Strategic Collaboration to develop CART-ddBCMA
09 Dec 2022 //
BUSINESSWIRE
Arcellx Announces Robust Responses from CART-ddBCMA Phase 1 Expansion Trial
09 Dec 2022 //
BIONJ
Arcellx Reports Third Quarter 2022 Financial Results And Business Progress
14 Nov 2022 //
PRESS RELEASE
Arcellx Announces Participation At The Morgan Stanley Annual Conference
07 Sep 2022 //
PRESS RELEASE
Arcellx Provides Business Highlights And Reports Q2 2022 Financial Results
15 Aug 2022 //
PRESS RELEASE
Arcellx Announces Closing Of Upsized Public Offering Of Common Stock
21 Jun 2022 //
PRESS RELEASE
Arcellx Announces Upsizing and Pricing of Follow-On Public Offering
16 Jun 2022 //
BIOSPACE
ASCO 2022: Surprising News in Cancer Research
10 Jun 2022 //
FOOL
ASCO: Arcellx`s CAR-T is matching J&J-Legend’s Carvykti, analyst says
07 Jun 2022 //
FIERCEBIOTECH
Arcellx Presents Continued Robust Long-Term Responses From Its CART-DdBCMA Phase 1 Expansion Trial
03 Jun 2022 //
PRESS RELEASE
Arcellx Appoints Olivia Ware to Board of Directors
16 May 2022 //
PRNEWSWIRE
Arcellx Begins Dosingin its Phase 1 Trial Evaluating ACLX-001
10 May 2022 //
PRNEWSWIRE
Arcellx Announces Closing of IPO and Exercise in Full of Underwriters’ Option
08 Feb 2022 //
GLOBENEWSWIRE
Biotech bear market be damned, CAR-T player Arcellx raises $123M IPO
05 Feb 2022 //
ENDPTS
Arcellx Announces Pricing of Initial Public Offering
04 Feb 2022 //
GLOBENEWSWIRE
With its lead CAR-T flashing some PhI data, Arcellx readies a jump to Nasdaq
19 Jan 2022 //
ENDPTS
Oxford Biomedica in license and supply deals with Novartis and Arcellx
11 Dec 2021 //
UKNEWS
Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial
04 Nov 2021 //
GLOBENEWSWIRE
Arcellx to Present Data from Phase 1 Study of CART-ddBCMA Demonstrating
18 May 2021 //
GLOBENEWSWIRE
Preclinical Data of Arcellx’s Novel Synthetic CAR-T Binding Domain Presented
13 May 2021 //
GLOBENEWSWIRE
Arcellx Closes $115 Million Series C Financing to Advance its Pipeline
13 Apr 2021 //
GLOBENEWSWIRE
Arcellx raises mega-round to put controllable CAR-T into the clinic
13 Apr 2021 //
GLOBNEWSWIRE
Arcellx Announces FDA Clearance of IND Application for ACLX-001
06 Apr 2021 //
GLOBENEWSWIRE
Arcellx Appoints Rami Elghandour as Chairman and Chief Executive Officer
26 Jan 2021 //
GLOBENEWSWIRE
Arcellx raises $85M to take anti-BCMA cell therapy into humans
04 Oct 2019 //
FIERCE BIOTECH
